EP0269408A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
TGF-Beta in the treatment of inflammatory disorders
Assignee: Genentech Inc
•
Filing: 1987-11-24
•
Granted: —
•
Expires: 2007-11-24
Abstract
Abstract Methods and compositions are provided for the treatment of inflammatory disorders such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus and the like. Therapeutically effective doses of Transforming Growth Factor-β are administered to patients in order to ameliorate these disorders.
Inventors
- 👤 Harold Michael Shepard
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 14:23
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
17 words
The use of transforming Growth Factor-β in the preparation of a medicament for treating an inflammatory disorder.
Claim 2
Dependent Claim
17 words
The use of transforming Growth Factor-β in the preparation of a medicament for treating an inflammatory disorder.
Claim 3
Dependent Claim
20 words
The use according to claim 1 wherein the disorder is accompanied by a Class II or Class III immune response.
Claim 4
Dependent Claim
19 words
The use according to claim 2 wherein the disorder is rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease.
Claim 5
Dependent Claim
36 words
The use according to claim 1 wherein medicament is in unit dosage form adapted to provide a therapeutic dosage effective to establish a TGF-β concentration in the inflamed tissue which is greater than about 0.1 ng/cc.
Claim 6
Dependent Claim
33 words
The use according to claim 4 wherein the disorder is rheumatoid arthritis and the dosage is effective to establish a TGF-β concentration in the synovial fluid of about from 0.5 to 15 ng/cc.
Claim 7
Dependent Claim
21 words
The use according to claim 1 wherein the TGF-β is formulated into a suppository and the disorder is inflammatory bowel disease.
Claim 8
Dependent Claim
40 words
The use according to claim 1 wherein the TGF-β is arranged for administration with an antagonist to γ-interferon, an antagonist to TNF-α, an antagonist to TNF-β, an antagonist to IL-1, a gold salt, penicillamine, a nonsteroidal anti-inflammatory agent and/or salicylate.
Claim 9
Dependent Claim
22 words
The use according to claim 5 wherein the TGF-β is formulated in a sustained release carrier and administered into a diarthrodial joint.
Claim 10
Dependent Claim
12 words
The use according to claim 8 wherein the carrier is a polylactide.
Claim 11
Dependent Claim
16 words
The use according to any one of the preceding claims wherein the TGF-β is human TGF-β.
Claim 12
Dependent Claim
5 words
A suppository which contains TGF-β.
Claim 13
Dependent Claim
5 words
A suppository which contains TGF-β.
Claim 14
Dependent Claim
41 words
A pharmaceutical preparation comprising TGF-β arranged for simultaneous or sequential administration with a substance selected from an antagonist to γ-interferon, an antagonist to TNF-α, an antagonist to TNF-β, an antagonist to IL-1, a nonsteroidal anti-inflammatory agent, penicillamine and a gold salt.
Claim 15
Dependent Claim
41 words
A pharmaceutical preparation comprising TGF-β arranged for simultaneous or sequential administration with a substance selected from an antagonist to γ-interferon, an antagonist to TNF-α, an antagonist to TNF-β, an antagonist to IL-1, a nonsteroidal anti-inflammatory agent, penicillamine and a gold salt.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.